103 related articles for article (PubMed ID: 31351861)
1. Neutrophil-related Variables Have Different Prognostic Effect Based on Primary Tumor Location in Patients With Metastatic Colorectal Cancer Receiving Chemotherapy.
Colloca GA; Venturino A; Guarneri D
Clin Colorectal Cancer; 2019 Dec; 18(4):e343-e348. PubMed ID: 31351861
[TBL] [Abstract][Full Text] [Related]
2. Reduction of derived neutrophil-to-lymphocyte ratio after four weeks predicts the outcome of patients receiving second-line chemotherapy for metastatic colorectal cancer.
Colloca GA; Venturino A; Guarneri D
Cancer Immunol Immunother; 2021 Apr; 70(4):1115-1125. PubMed ID: 33123753
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Hematologic and Other Prognostic Markers in Metastatic Colorectal Cancer.
Mercier J; Voutsadakis IA
J Gastrointest Cancer; 2019 Sep; 50(3):493-506. PubMed ID: 29704170
[TBL] [Abstract][Full Text] [Related]
4. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
Song A; Eo W; Lee S
World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
[TBL] [Abstract][Full Text] [Related]
5. Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer.
Sunakawa Y; Yang D; Cao S; Zhang W; Moran M; Astrow SH; Hsiang J; Stephens C; Tsuji A; Takahashi T; Tanioka H; Negoro Y; Takagane A; Tani S; Yamaguchi T; Eto T; Fujii M; Ichikawa W; Lenz HJ
Clin Colorectal Cancer; 2018 Dec; 17(4):e741-e749. PubMed ID: 30219280
[TBL] [Abstract][Full Text] [Related]
6. Skin Disorders and Primary Tumor Location as Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated with Cetuximab and Chemotherapy.
Takada S; Sagawa T; Fujikawa K; Tahatsu K; Fukai Y; Hashishita H; Takahashi Y; Endo M
Asian Pac J Cancer Prev; 2018 Aug; 19(8):2325-2330. PubMed ID: 30141310
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer.
Chua W; Charles KA; Baracos VE; Clarke SJ
Br J Cancer; 2011 Apr; 104(8):1288-95. PubMed ID: 21448173
[TBL] [Abstract][Full Text] [Related]
8. The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy.
Salati M; Caputo F; Cunningham D; Marcheselli L; Spallanzani A; Rimini M; Gelsomino F; Reggiani-Bonetti L; Andrikou K; Rovinelli F; Smyth E; Baratelli C; Kouvelakis K; Kalaitzaki R; Gillbanks A; Michalarea V; Cascinu S; Braconi C
Eur J Cancer; 2019 Aug; 117():84-90. PubMed ID: 31276980
[TBL] [Abstract][Full Text] [Related]
9. Second-generation inflammation-related scores are more effective than systemic inflammation ratios in predicting prognosis of patients with unresectable or metastatic pancreatic cancer receiving cytotoxic chemotherapy.
Colloca GA; Venturino A; Guarneri D
Med Oncol; 2018 Oct; 35(12):158. PubMed ID: 30374617
[TBL] [Abstract][Full Text] [Related]
10. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer.
Chen ZY; Raghav K; Lieu CH; Jiang ZQ; Eng C; Vauthey JN; Chang GJ; Qiao W; Morris J; Hong D; Hoff P; Tran H; Menter DG; Heymach J; Overman M; Kopetz S
Br J Cancer; 2015 Mar; 112(6):1088-97. PubMed ID: 25688736
[TBL] [Abstract][Full Text] [Related]
11. The prognostic significance of the advanced lung cancer inflammation index in patients with unresectable metastatic colorectal cancer: a retrospective study.
Shibutani M; Maeda K; Nagahara H; Fukuoka T; Matsutani S; Kimura K; Amano R; Hirakawa K; Ohira M
BMC Cancer; 2019 Mar; 19(1):241. PubMed ID: 30885163
[TBL] [Abstract][Full Text] [Related]
12. Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies.
Boeckx N; Koukakis R; Op de Beeck K; Rolfo C; Van Camp G; Siena S; Tabernero J; Douillard JY; André T; Peeters M
Clin Colorectal Cancer; 2018 Sep; 17(3):170-178.e3. PubMed ID: 29627309
[TBL] [Abstract][Full Text] [Related]
13. Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS.
Yang J; Guo X; Wang M; Ma X; Ye X; Lin P
Sci Rep; 2017 Dec; 7(1):17166. PubMed ID: 29215037
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials.
Sunakawa Y; Ichikawa W; Tsuji A; Denda T; Segawa Y; Negoro Y; Shimada K; Kochi M; Nakamura M; Kotaka M; Tanioka H; Takagane A; Tani S; Yamaguchi T; Watanabe T; Takeuchi M; Fujii M; Nakajima T
Clin Colorectal Cancer; 2017 Sep; 16(3):e171-e180. PubMed ID: 27856123
[TBL] [Abstract][Full Text] [Related]
15. Treatment of metastatic colorectal cancer with or without bevacizumab: can the neutrophil/lymphocyte ratio predict the efficiency of bevacizumab?
Dirican A; Varol U; Kucukzeybek Y; Alacacioglu A; Erten C; Somali I; Can A; Demir L; Bayoglu IV; Akyol M; Yildiz Y; Koyuncu B; Coban E; Tarhan MO
Asian Pac J Cancer Prev; 2014; 15(12):4781-6. PubMed ID: 24998541
[TBL] [Abstract][Full Text] [Related]
16. Preoperative Neutrophil-to-Lymphocyte Ratio is a Better Prognostic Serum Biomarker than Platelet-to-Lymphocyte Ratio in Patients Undergoing Resection for Nonmetastatic Colorectal Cancer.
Choi WJ; Cleghorn MC; Jiang H; Jackson TD; Okrainec A; Quereshy FA
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S603-13. PubMed ID: 25900206
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis.
Wu Y; Li C; Zhao J; Yang L; Liu F; Zheng H; Wang Z; Xu Y
World J Surg Oncol; 2016 Nov; 14(1):289. PubMed ID: 27852294
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts Survival After TAS-102 Treatment of Patients With Metastatic Colorectal Cancer.
Matsuda A; Yamada T; Matsumoto S; Sakurazawa N; Kawano Y; Shinozuka E; Sekiguchi K; Suzuki H; Yoshida H
Anticancer Res; 2019 Aug; 39(8):4343-4350. PubMed ID: 31366528
[TBL] [Abstract][Full Text] [Related]
19. Primary tumor location as a prognostic factor in metastatic colorectal cancer.
Loupakis F; Yang D; Yau L; Feng S; Cremolini C; Zhang W; Maus MK; Antoniotti C; Langer C; Scherer SJ; Müller T; Hurwitz HI; Saltz L; Falcone A; Lenz HJ
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25713148
[TBL] [Abstract][Full Text] [Related]
20. Value of tumor size as a prognostic factor in metastatic colorectal cancer patients after chemotherapy: a population-based study.
Yan Q; Zhang K; Guo K; Liu S; Wasan HS; Jin H; Yuan L; Feng G; Shen F; Shen M; Ma S; Ruan S
Future Oncol; 2019 May; 15(15):1745-1758. PubMed ID: 31038364
[No Abstract] [Full Text] [Related]
[Next] [New Search]
